In patients with neurological symptoms associated with severe COVID-19 cases, autoantibodies in serum and sometimes in CSF of neuronal targets have been identified (anti Yo antibodies, anti-NMDA receptor antibodies, and anti-myelin antibodies) suggesting a dysregulation of the immune system in SARS-CoV-2 infection, which can make a connection with GBS, MS, myelitis, and encephalitis cases reported after the infection [5,12,13,14,115]. The gene discussed is CDR2; the disease is COVID-19.